Cancer Frequency in <scp>MuSK</scp> Myasthenia Gravis and Histological Evidence of Paraneoplastic Etiology-Reference-Cited by-同舟云学术

Cancer Frequency in MuSK Myasthenia Gravis and Histological Evidence of Paraneoplastic Etiology

Published:2024-07-15 Issue: Volume: Page:
ISSN:0364-5134
Container-title:Annals of Neurology
language:en
Short-container-title:Annals of Neurology

Author:

Falso Silvia¹,Gessi Marco²,Marini Sofia¹,Benvenuto Roberta²,Sabatelli Eleonora³,D'Amati Antonio⁴^ORCID,Marini Martina¹,Evoli Amelia¹³^ORCID,Iorio Raffaele¹³^ORCID

Affiliation:

1. Department of Neuroscience Università Cattolica del Sacro Cuore Rome Italy

2. Neuropathology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS Rome Italy

3. Neurology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS Rome Italy

4. Gynecopathology and Breast Pathology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS Rome Italy

Abstract

Cancer frequency in muscle‐specific kinase myasthenia gravis (MuSK‐MG) has not yet been explored and the mechanisms leading to the formation of MuSK IgG remain elusive. We aimed to explore cancer frequency in MuSK‐MG patients and to assess MuSK expression in cancer cells from 2 tumors occurred in this cohort. Immunohistochemistry on tumor specimens revealed the expression of MuSK in the cancer cells from primary mediastinal B cell lymphoma and endometrial carcinoma. Twenty‐one males and 73 females were enrolled. Fifteen cancers occurred in 13 of 94 patients (13.8%). Patients with cancer were significantly older at time of MuSK‐MG onset. ANN NEUROL 2024

Funder

Rare Diseases Clinical Research Network

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ana.27033

Reference15 articles.

1. Myasthenia gravis with antibodies to MuSK: an update

2. IgG4 subclass antibodies impair antitumor immunity in melanoma

3. Possible Association Between IgG4-Associated Systemic Disease With or Without Autoimmune Pancreatitis and non-Hodgkin Lymphoma

4. Serum exosomes and cytokines promote a T-helper cell type 2 environment in the peripheral blood of glioblastoma patients

5. Myasthenia gravis: the changing treatment landscape in the era of molecular therapies